Have Insiders Been Buying Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares This Year?

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell Sangamo Therapeutics, Inc. (NASDAQ:SGMO), you may well want to know whether insiders have been buying or selling.

What Is Insider Selling?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, rules govern insider transactions, and certain disclosures are required.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Columbia University study found that ‘insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers’.

See our latest analysis for Sangamo Therapeutics

The Last 12 Months Of Insider Transactions At Sangamo Therapeutics

Over the last year, we can see that the biggest insider purchase was by Director Roger Jeffs for US$100k worth of shares, at about US$13.56 per share. So it’s clear an insider wanted to buy, even at a higher price. It’s very possible they regret the purchase, but it’s more likely they are bullish about the company. We generally consider it a positive if insiders have been buying on market, even above the current price.

Happily, we note that in the last year insiders bought 11.41k shares for a total of US$146k. In total, Sangamo Therapeutics insiders bought more than they sold over the last year. The average buy price was around US$12.76. This is nice to see since it implies that insiders might see value around current prices (around US$12.29). You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqGS:SGMO Recent Insider Trading, April 3rd 2019
NasdaqGS:SGMO Recent Insider Trading, April 3rd 2019

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Does Sangamo Therapeutics Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Based on our data, Sangamo Therapeutics insiders have about 0.2% of the stock, worth approximately US$3.0m. We prefer to see high levels of insider ownership.

What Might The Insider Transactions At Sangamo Therapeutics Tell Us?

It doesn’t really mean much that no insider has traded Sangamo Therapeutics shares in the last quarter. However, our analysis of transactions over the last year is heartening. We’d like to see bigger individual holdings. However, we don’t see anything to make us think Sangamo Therapeutics insiders are doubting the company. Of course, the future is what matters most. So if you are interested in Sangamo Therapeutics, you should check out this free report on analyst forecasts for the company.

If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.